Description
Novel thymic cellular populations and uses thereofWO2008134805A1 - WIPO (PCT)
Abstract: The present invention relates generally to novel thymic cellular populations and, more particularly, to novel thymic epithelial cellular populations. Most particular, the present invention is directed to novel thymic epithelial progenitor cell populations. The cellular populations of the present invention are useful in a wide range of clinical and research settings including, inter alia, the in vitro or in vivo generation of thymic epithelial cell populations and the therapeutic or prophylactic treatment of a range of conditions via the administration of these cells. Also facilitated is the design of in vitro based screening systems for testing the therapeutic impact and/or toxicity of potential treatment or culture regimes to which thymic epithelial cells may be exposed. In another aspect, the present invention is directed to a method of identifying thymic epithelial cellular subpopulations and, more particularly, thymic epithelial progenitors by screening for the co-expression of markers including MHC Class II, UEA1 and Ly51. This method is useful in a range of applications including, but not limited to, assessing or monitoring for the presence of thymic epithelial cell populations and/or facilitating the isolation of or enrichment for these cellular populations of use in a range of research and clinical applications.
| Period | 13 Nov 2008 |
|---|---|
| Held at | Norwood Immunology Ltd, Australia, Victoria |
| Degree of Recognition | International |